期刊
ONCOLOGIST
卷 14, 期 6, 页码 621-636出版社
WILEY
DOI: 10.1634/theoncologist.2008-0272
关键词
Malignant glioma; Glioblastoma; Angiogenesis; Vascular endothelial growth factor; Cerebral edema
类别
资金
- NCI NIH HHS [P01 CA080124] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [P01CA080124] Funding Source: NIH RePORTER
Currently, adult glioblastoma (GBM) patients have poor outcomes with conventional cytotoxic treatments. Because GBMs are highly angiogenic tumors, inhibitors that target tumor vasculature are considered promising therapeutic agents in these patients. Encouraging efficacy and tolerability in preliminary clinical trials suggest that targeting angiogenesis may be an effective therapeutic strategy in GBM patients. However, the survival benefits observed to date in uncontrolled trials of antiangiogenic agents have been modest, and several obstacles have limited their effectiveness. This article reviews the rationale for antiangiogenic agents in GBM, their potential mechanisms of action, and their clinical development in GBM patients. Although challenges remain with this approach, ongoing studies may improve upon the promising initial benefits already observed in GBM patients. The Oncologist 2009; 14: 621-636
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据